• AgoraVox sur Twitter
  • RSS
  • Agoravox TV
  • Agoravox Mobile


Commentaire de njama

sur 300 millions € /an pour les hôpitaux, versus 3 Milliards € la Iere année d'obligation du Gardasil Incroyable mais vrai


Voir l'intégralité des commentaires de cet article

njama njama 24 novembre 2019 18:28

@Eric F
Oui c’est tout à fait ça avant qu’elle ne retourne sa culotte sans s’en expliquer en 2007 la FDA (Food & Drug Adminstration) publiait sur son site dans un document que les infections HPV ne causent pas le cancer du col de l’utérus, même celles causées par des HPV dits à « hauts risques », mais que seules les infections HPV « persistantes » peuvent éventuellement induire des lésions précancéreuses au niveau du col de l’utérus.

Page 8
Based on new scientific information published in the past 15 years, it is now generally agreed that identifying and typing HPV infection does not bear a direct relationship to stratification of the risk for cervical cancer. Most acute infections caused by HPV are sel-limiting [1, 4-7]. It is the persistent HPV infection that may act as a tumor promoter in cancer induction [8-11]. Identifying and typing HPV is an important tool for following patients with persistent HPV infection. Repeated sequential transient HPV infections, even when caused by « high-risk » HPVs, are characteristically not associated with high risk of developping squamous intraepithelial lesions, a precursor of cervical cancer.

A woman found to be positive for the same strain (genotype) of HPV on repeated testing is highly likely suffering from a persistent HPV infection and is considered to be at high risk of developing precancerous intraepithelial lesions in the cervix. It is the persistent infection, not the virus, that determines the cancer risk.

The FDA has accepted the above interpretation of current medical science, as reflected in its March 31, 2003 announcement on aproval of the digene HC2 High-Risk HPV DNA Test while making the following public statements on record [I].

« The FDA today approved expanded use of a laboratory test detect the presence in women of human papilomavirus (HPV), one of the most common sexualily transmitted infections. »

« The HPV DNA test does not test for cancer, but for HPV viruses that can cause cell changes in the cervix. If left untreated, these changes can eventually lead to cancer in some women. »

« Most women who become infected with HPV are able to eradicate the virus and suffer no apparent long-term consequences to their health. But a few women develop a persistent infection that can eventually lead to pre-cancerous changes in the cervix. »
« ...most infections are short-lived and not associated with cervical cancer. »

Page 10
« Historically, HPV testing [15] was introduced to compensate for the poor sensitivity and specificity of the Pap smear cytology often used as a diagnostic tool for borderline precancerous lesions. The only FDA approved Digene Hybrid Capture 2 (HC2) assay is commonly used to determine if a cervicovaginal lavage sample harbors »high-risk« HPVs [16], as an adjunctive test for evaluation of the cytologically borderline cases [17-19]. However, it is now recognized that persistent infection of a »high-risk« HPV, not the HPV virus itself, is the pivotal promoter incausing cervical precancerous lesions and cancer [7-10].
Most of HPV infections, even caused by »high-risk« genotypes, are transient with normal Pap cytology in sexually active young women [1, 3-6]. In 93% of the initially infected women, the same viral type is not detected upon re-examination four menstrual cycles later [20]. The median duration of positivity detectable by PCR for a specific HPV type in these young women is 168 days [21]. Multiple »high-risk« HPV infections do not constitute a higher risk for the development of cervical neoplasia when compared with single high-risk HPV infection [22]. For the development and maintenance of a high-grade squamous intra epithelial lesion (SIL), the risk is greatest in women positive for the same genotype of HPV on repeated testing [7-9]. Viral load is not a useful parameter to predict high-grade SIL [23]. High-grade SIL is often associated with a viral DNA load lower than that observed in less severely affected cells [24] »

Le document FDA “Reclassification Petition for Human Papillomavirus (HPV) DNA, Nested Polymerase Chain Reaction (PCR) Detection” published March 7, 2007. se retrouve sur web.archive.org

(il faut faire un copier-coller du lien et supprimer l’espace entre http et ://www... pour qu’il fonctionne)

https://web.archive.org/web/20110926180322/http ://www.fda.gov/ohrms/dockets/dockets/07p0210/07p-0210-ccp0001-01-vol1.pdf

ou ici : https://www.naturalnews.com/downloads/FDA-HPV.pdf

Répondre Signaler un abus

Voir ce commentaire dans son contexte


Derniers commentaires




Palmarès